Experimental and Clinical Psychopharmacology
November 27, 2023
Jakub Greń, Ingmar Gorman, Anastasia Ruban et al.
27 citations
Psychedelic integration (PI) refers to practices that aim to minimize harms or maximize benefits after psychedelic use. Although PI is considered essential in psychedelic-assisted therapy, existing models lack empirical support and are not evidence-based. With psychedelic use increasing, the article calls for scientific efforts to develop, examine, and evaluate PI methods. It summarizes current literature, suggests research avenues, and discusses limitations and challenges of PI-focused research.
Frontiers in Psychology
October 12, 2023
Jakub Greń, Filip Tylš, Michał Lasocik et al.
21 citations
Mental health professionals increasingly encounter clients who have had psychedelic experiences, yet graduate training in psychiatry, psychology, and counseling does not prepare them for this work. To address this gap, an international bottom-up project used literature reviews and roundtable discussions to develop comprehensive guidelines for psychedelic integration. The guidelines cover theoretical and practical aspects, including psychedelic effects, a definition of integration, theoretical considerations, a model for organizing integration practice, an overview of current models, and specific interventions from various psychotherapeutic approaches. These guidelines are intended as a resource for any mental health specialist supporting individuals with psychedelic experiences.
Psychiatr Res Clin Pract
February 11, 2025
Jules Evans, Marc Aixalà, Brian T. Anderson et al.
18 citations
Thirty psychedelic researchers identified critical gaps in knowledge about harms from psychedelic use, including how to define those harms, predict them, and treat them effectively. They recommend better online information, peer support groups, affordable therapy, and psychiatric consultation for people experiencing post-psychedelic difficulties. The researchers also call for improved funding for a psychedelic safety net, suggesting that psychedelic philanthropists, investors, and companies commit 1% of their investment to support safety measures such as research and support services. The article outlines practical steps to make the field of psychedelic medicine safer.